GDM: Prevention of GDM Diagnosis (2008)
- women between 24 and 29 wk of pregnancy
- singleton pregnancy
- >16 y of age
- spoke English
- had access to a phone
- planned to continue their care at 1 of the research sites
- signed an informed conscent. Study protocols approved by Institution Review Boards of the School of Medicine at the University of North Carolina at Chapel Hill and Wake Medical Center.
- racial group other than white or black
- second pregnancy
- preexisting diabetes
- no glucose screening data
- a high glucose screening results without an oral glucose tolerance test, thus unclassified
- missing dietary data
- missing body mass index
- women with total estimated energy intake less than the 5th percentile or greater than the 95th percentile
Recruitment: Data from the Pregnancy, Infection and Nutrition (PIN) Study in central North Carolina.
Design : Prospective cohort study
Blinding used: not applicable
Intervention: Women with GDM received diet treatment, insulin treatment, or both at both clinics and women with IGT were not treated at either clinic.
Statistical Analysis:
- bivariate analysis of sociodemographic characteristics and dietary variables with glucose status was performed.
- Chi-square analysis was conducted to test the differences in categorical variables
- one-way analysis of variance with a Bonferroni correction for multiple comparisons was used for continuous variables
- multinominal logistic regresssion was used to calculate the likelihood of developing IGT or GDM compared with normal glucose tolerance while adjusting for potential confounders. Variables that were associated with both glucose status and dietary variables and resulted in at least a 10% change in the IGT or GDM ß coefficients were retained in the models.
- The partition method was used to evaluate the effect of adding dietary fat or carbohydrates to the diet. Nutrients were partitioned into calories from fat, carbohydrates, and protein. Variables were scaled to to represent risk per 100 kcal of the micronutrient.
- Model 1 reported the effect of adding dietary fat to the diet
- Model 2 reported the the effects of adding carbohydrates to the diet.
- Models 3 through 5 evaluated the effect of theoretically substituting one macronutrient for another, allowing the researchers to compare isocaloric diets.
- To evaluate the potential for effect modification by race or weight gain on the relation between diet and glucose status, researchers evaluated diet-by-race and diet-by-weight gain interaction terms in the models when P values were <=1.0.
- To facilitate interpretation of the results, the predicted probabilities of IGT and GDM were calculated from the coefficients of the models that showed significant dietary effects (Models 2 and 3). The predicted probabilities were calculated for the various dietary scenarios.
Timing of Measurements
- several questionnaires were self-administered at the time of recruitment including a food-frequency questionnaire
- contacted by telephone within 2 weeks of recruitment regarding current and pregravid health behaviors and sociodemographic characteristics
- dietary intake information assessed during the second trimester
- maternal height measured during clinic visits
- physical activity - participation in a regular or strenuous physical activity was assessed 3 months before becoming pregnant and during the first and second trimesters.
- cigarette smoking habits assessed during the first 6 months of the pregnancy.
Dependent Variables
Glucose intolerance:
- information obtained from hospital computer data base and medical charts
- glucose tolerance status involved two-steps: 1.) initial screening test measuring the plasma glucose concentration 1 h after a 50-g glucose challenge test (random screen that does not require fasting state); 2.) site specific protocols established the cutoffs for the follow-up testing (these were different for each clinic because disagreement existed about which cutoff represented risk).
- OGTT - the test was conducted in the fasting state with glucose analysis performed at fasting and 1, 2, and 3h after the oral glucose load. A value of >=140 mg.dL at the Univ of North Carolina sites and a value of >=130 mg/dl at the Wake Medical Center sites indicated the need for a full 3 h,100 g oral glucose-tolerance test. Tests are performed on serum samples with the use of with the use of the glucose oxidase method. The Carpenter and Coustan cutoff of 95mg/dL for fasting, 180 mg/dL for 1-h, 155 mg/dL for 2-h, and 135 mg/dL for 3-h were used for abnormal values.
- IGT was defined as one abnormal value form the OGTT.
- Normal glucose tolerance was defined as having a normal or high result on the glucose challenge test but no high values on the OGTT.
- GDM were defined by 2 abnormal values on the OGTT.
Dietary data - variables of interest: macronutrients and total energy.
- dietary intake (2nd trimester) assessed by using a modified food frequency questionnaire originally developed by Block et al. Modifications were made to include local foods, make the questionnaire specific to the pregnancy time period, and include more food specific portion sizes.
- the validity of the food-frequency questionnaire in the PIN population was assesed among 99 women by comparing nutrient results from the food frequency questionnaire with three 24-hr dietary recalls colllected at random on nonconsecutive days.
- the deattenuated Pearson correlation coefficients for total energy and micronutrients intake for the food frequency questionnaire and the 24-h recall were 0.35 for total energy, 0.43 for fats, 0.44 for protein, and 0.26 for carbohydrates. These results for energy, fat, and protein were similar to a recent comparison of a food frequency questionnaire and 10 day food record intakes in pregnant women; the results for carbohydrates were lower (energy, r= 0.24; fats, r=0.48; protein, r=0.55; and carbohydrates, r=0.49).
Independent Variables
- prepregnancy BMI (kg/m2) was classified according to guidelines established by the Institute of Medicine: underweight, <19.8;normal weight, 19.8-26; overweight, >26-29; and obese, >29. Recalled prepregnancy weight was obtained from the medical record or the screening questionnaire. If the first weight measurement was after 15 weeks of gestation, a prepregnancy weight could not be imputed. In those cases, underweight and normal weight were combined and used as the reference category. Height was measured during clinic visits.
- maternal age
- weight gain
- physical activity-participation in a regular or strenuous physical activity was assessed 3 months before becoming pregnant and during the first and second trimesters.
- race-self identified during phone call or taken from medical chart
- family income was represented as a percentage of the poverty index according to U.S. Bureau of Census 1996 poverty guidelines
- cigarette smoking habits assessed during the first 6 months of the pregnancy.
Control Variables
Initial N: 2898 pregnant women
Attrition (final N): 1698 used in analysis
Age: See Table I
Ethnicity: white or black
Other relevant demographics:
Anthropometrics
Location: Department of Nutrition and Maternal and Child Health, School of Public Health and the Carolina Population Center, University of North Carolina, Chapel Hill.
The overall prevalence of IGT in the cohort was 2.6%, and that of GDM was 5.2% (see Table I).
Table 1. Characteristics of the participants in the Pregnancy, Infection, and Nutrition Study by glucose tolerance status1
Variable |
Normal(n=1565) |
IGT(n=44) |
GDM(n=89) |
p2 |
Race (%) |
- |
- |
- |
0.002 |
White |
60 |
73 |
76 |
- |
Black |
40 |
27 |
24 |
- |
Marital status (%) |
- |
- |
- |
0.008 |
Single |
41 |
25 |
25 |
- |
Married |
52 |
61 |
65 |
- |
Other |
7 |
14 |
10 |
- |
Poverty index, n=1507 (%) |
- |
- |
- |
0.78 |
<185% |
53 |
59 |
57 |
- |
185-350% |
20 |
22 |
17 |
- |
>350% |
27 |
19 |
26 |
- |
Smoked, n=1594 (%) |
25 |
25 |
24 |
0.97 |
Physical activity, n=1600 (%) |
- |
- |
- |
- |
During 3 mo before pregnancy |
25 |
28 |
17 |
0.22 |
During first trimester |
16 |
16 |
10 |
0.33 |
During second trimester |
9.5 |
9.3 |
3.6 |
0.19 |
Pregravid BMI (kg/m2) |
25.0 ±6.53 |
28.4±7.9 |
30.1±7.7 |
0.001 |
BMI categories (%) |
- |
- |
- |
0.001 |
Underweight or |
- |
- |
- |
- |
normal weight (BMI<26) |
67 |
45 |
35 |
- |
Overweight (BMI>26-29) |
11 |
16 |
15 |
- |
Obese (BMI>29) |
22 |
39 |
50 |
- |
Mothers' age (y) |
26±6.2 |
29±6.0 |
28±5.6 |
0.001 |
Mothers'education (y) |
13.6±2.9 |
13.7±2.2 |
14.0±2.8 |
0.54 |
Parity, n=1692 |
0.8±1.1 |
1.1±1.1 |
0.9±0.9 |
0.16 |
Mothers' height (m) |
1.65±0.07 |
1.64±0.07 |
1.64±0.07 |
0.07 |
1 IGT,impaired glucose tolerance; GDM, gestatational diabetes mellitus
2 P values are from overall chi-square test for categorical variables or from ANOVA with Bonferroni correction for continuous variables.
3 Mean±SD
Only the intake of carbohydrates and fat differed by glucose status (Table 2).
Table 2 Mean dietary composition by glucose tolerance status of women in thr Pregnancy, Infection, and Nutrition Study 1
Normal IGT GDM P2 2603±995 2431±844 2572±939 0.51 14±2.8 15±2.5 14±2.7 0.15 53±7.4 50±6.5 51±7.1 0.0004 33±6.3 35±5.9 35±5.9 0.001
Total energy (kcal)
Protein (% of energy)
Carbohydrate (% of energy)
Fat (% of energy)
1 Mean ±SD. n=1698. IGT, impaired glucose tolerance; GDM, gestational diabetes mellitus.
2 P values are from an overall chi-square test for macronutrients or from an ANOVA with Bonferroni correction for total energy.
The relative risk ratios and 95% confidence intervals are presented in Table 3. Model 2: showed that adding 100 kcal carbohydrates was associated with a 12% decrease in risk of IGT and a 9% decrease risk of GDM; Model 3 showed that substituting fat for carbohydrate resulted in significant increase in i risk of both IGT and GDM.
Table 3 Relative risk ratios (RRs) of impaired glucose tolerance (IGT) and gestational diabetes mellitus (GDM)1
IGT |
GDM |
|||
RR(95% CI) |
P |
RR(95% CI) |
P |
|
Additional models: calories of micronutrients2 |
- |
- |
- |
- |
Model 1: Adding fat |
1.1(0.97,1.30) |
0.14 |
1.1(1.0,1.20) |
0.06 |
Model 2: Adding carbohydrate |
0.9(0.79,0.98) |
0.02 |
0.9(0.85,0.98) |
0.01 |
Substituting models: percentage of macronutrients3 |
- |
- |
- |
- |
Model 3: Substituting fat for carbohydrate |
1.1(1.02,1.12) |
0.006 |
1.1(1.02,1.10) |
0.002 |
Model 4: Substituting fat for protein |
1.0(0.93,1.15) |
0.58 |
1.0(0.94,1.10) |
0.68 |
Model 5: Substituting carbohydrates for protein |
0.9(0.90,1.06) |
0.41 |
0.9(0.90,1.03) |
0.24 |
1n=1698. All models were adjusted for BMI, maternal age, and race.
2 Additional models are per 100 kcal for carbohydrate.
3 Substitution models are adjusted for total calories and per 1%
Other Findings
- The predicted probabilities of IGT and GDM were higher for white women than for black women at every fat intake level.
- The predicted probabilities of IGT and GDM decreased with the additional energy from carbohydrates.
- In an isocaloric diet, an increase in carbohydrate intake as a percentage of energy with a simultaneous decrease in fat intake as a percentage of energy significantly reduced the risk of glucose intolerance.
- Increasing carbohydrates without decreasing fat and thus not controlling for total energy intake also significantly reduces the risk of both IGT and GDM.
- the validity of the food-frequency questionnaire in the PIN population was assesed among 99 women by comparing nutrient results from the food frequency questionnaire with three 24-hr dietary recalls colllected at random on nonconsecutive days.
- The interaction terms were not significant.
- Separate predicted probabilities were presented for black and white women because the prevalences of IGT and GDM were significantly different by race.
Limitations
- the assessment of dietary exposure could result in a bias estimate effect
- the correlation coefficient for carbohydrates was 0.26. Validation studies have shown that correlation coefficients for carbohydrates was 0.26. Validation studies have shown that correlation coefficiients <0.4 can attenuate an association between an exposure and an outcome, and thus the estimate of a carbohydrate effect may be conservative.
- the effect of residual confounding from sources not measured could influence the estimates
- the analysis population somewhat underrepresented black women, which could influence the estimates.
Government: | NIGMS, NICHD |
University/Hospital: | Dept. of Nutrition Clinical Nutrition Research Center |
The limitations and critique of the study, as stated by the authors appear to be very appropriate.
Analytical longitudinal surveys refer to what epidemiologists term prospective or cohort studies. A Cohort Study is a study in which patients who presently have a certain condition and/or receive a particular treatment are followed over time and compared with another group who are not affected by the condition under investigation. Studies of this kind provide a better opportunity than one time cross sectional studies to examine whether certain behaviors do in fact lead to (or cause) the disease.
Quality Criteria Checklist: Primary Research
|
|||
Relevance Questions | |||
1. | Would implementing the studied intervention or procedure (if found successful) result in improved outcomes for the patients/clients/population group? (Not Applicable for some epidemiological studies) | Yes | |
2. | Did the authors study an outcome (dependent variable) or topic that the patients/clients/population group would care about? | Yes | |
3. | Is the focus of the intervention or procedure (independent variable) or topic of study a common issue of concern to dieteticspractice? | Yes | |
4. | Is the intervention or procedure feasible? (NA for some epidemiological studies) | Yes | |
Validity Questions | |||
1. | Was the research question clearly stated? | Yes | |
1.1. | Was (were) the specific intervention(s) or procedure(s) [independent variable(s)] identified? | Yes | |
1.2. | Was (were) the outcome(s) [dependent variable(s)] clearly indicated? | Yes | |
1.3. | Were the target population and setting specified? | Yes | |
2. | Was the selection of study subjects/patients free from bias? | ??? | |
2.1. | Were inclusion/exclusion criteria specified (e.g., risk, point in disease progression, diagnostic or prognosis criteria), and with sufficient detail and without omitting criteria critical to the study? | Yes | |
2.2. | Were criteria applied equally to all study groups? | Yes | |
2.3. | Were health, demographics, and other characteristics of subjects described? | Yes | |
2.4. | Were the subjects/patients a representative sample of the relevant population? | No | |
3. | Were study groups comparable? | Yes | |
3.1. | Was the method of assigning subjects/patients to groups described and unbiased? (Method of randomization identified if RCT) | Yes | |
3.2. | Were distribution of disease status, prognostic factors, and other factors (e.g., demographics) similar across study groups at baseline? | Yes | |
3.3. | Were concurrent controls or comparisons used? (Concurrent preferred over historical control or comparison groups.) | N/A | |
3.4. | If cohort study or cross-sectional study, were groups comparable on important confounding factors and/or were preexisting differences accounted for by using appropriate adjustments in statistical analysis? | Yes | |
3.5. | If case control study, were potential confounding factors comparable for cases and controls? (If case series or trial with subjects serving as own control, this criterion is not applicable.) | N/A | |
3.6. | If diagnostic test, was there an independent blind comparison with an appropriate reference standard (e.g., "gold standard")? | N/A | |
4. | Was method of handling withdrawals described? | Yes | |
4.1. | Were follow-up methods described and the same for all groups? | Yes | |
4.2. | Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) | Yes | |
4.3. | Were all enrolled subjects/patients (in the original sample) accounted for? | Yes | |
4.4. | Were reasons for withdrawals similar across groups? | N/A | |
4.5. | If diagnostic test, was decision to perform reference test not dependent on results of test under study? | N/A | |
5. | Was blinding used to prevent introduction of bias? | N/A | |
5.1. | In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? | N/A | |
5.2. | Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) | N/A | |
5.3. | In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? | N/A | |
5.4. | In case control study, was case definition explicit and case ascertainment not influenced by exposure status? | N/A | |
5.5. | In diagnostic study, were test results blinded to patient history and other test results? | N/A | |
6. | Were intervention/therapeutic regimens/exposure factor or procedure and any comparison(s) described in detail? Were interveningfactors described? | N/A | |
6.1. | In RCT or other intervention trial, were protocols described for all regimens studied? | N/A | |
6.2. | In observational study, were interventions, study settings, and clinicians/provider described? | N/A | |
6.3. | Was the intensity and duration of the intervention or exposure factor sufficient to produce a meaningful effect? | N/A | |
6.4. | Was the amount of exposure and, if relevant, subject/patient compliance measured? | N/A | |
6.5. | Were co-interventions (e.g., ancillary treatments, other therapies) described? | N/A | |
6.6. | Were extra or unplanned treatments described? | N/A | |
6.7. | Was the information for 6.4, 6.5, and 6.6 assessed the same way for all groups? | N/A | |
6.8. | In diagnostic study, were details of test administration and replication sufficient? | N/A | |
7. | Were outcomes clearly defined and the measurements valid and reliable? | ??? | |
7.1. | Were primary and secondary endpoints described and relevant to the question? | Yes | |
7.2. | Were nutrition measures appropriate to question and outcomes of concern? | Yes | |
7.3. | Was the period of follow-up long enough for important outcome(s) to occur? | Yes | |
7.4. | Were the observations and measurements based on standard, valid, and reliable data collection instruments/tests/procedures? | Yes | |
7.5. | Was the measurement of effect at an appropriate level of precision? | Yes | |
7.6. | Were other factors accounted for (measured) that could affect outcomes? | No | |
7.7. | Were the measurements conducted consistently across groups? | Yes | |
8. | Was the statistical analysis appropriate for the study design and type of outcome indicators? | Yes | |
8.1. | Were statistical analyses adequately described and the results reported appropriately? | Yes | |
8.2. | Were correct statistical tests used and assumptions of test not violated? | Yes | |
8.3. | Were statistics reported with levels of significance and/or confidence intervals? | Yes | |
8.4. | Was "intent to treat" analysis of outcomes done (and as appropriate, was there an analysis of outcomes for those maximally exposed or a dose-response analysis)? | Yes | |
8.5. | Were adequate adjustments made for effects of confounding factors that might have affected the outcomes (e.g., multivariate analyses)? | Yes | |
8.6. | Was clinical significance as well as statistical significance reported? | Yes | |
8.7. | If negative findings, was a power calculation reported to address type 2 error? | N/A | |
9. | Are conclusions supported by results with biases and limitations taken into consideration? | Yes | |
9.1. | Is there a discussion of findings? | Yes | |
9.2. | Are biases and study limitations identified and discussed? | Yes | |
10. | Is bias due to study's funding or sponsorship unlikely? | Yes | |
10.1. | Were sources of funding and investigators' affiliations described? | Yes | |
10.2. | Was the study free from apparent conflict of interest? | Yes | |